Several silver foil pill packs with white pills
FDA Authorizes Pfizer’s Paxlovid, First Oral Therapy for COVID-19
Given within three days of symptom onset, the pill combination was nearly 90 percent effective at preventing high-risk patients from developing severe illness in a clinical study.
ABOVE: © ISTOCK.COM, KENISHIROTIE
FDA Authorizes Pfizer’s Paxlovid, First Oral Therapy for COVID-19
FDA Authorizes Pfizer’s Paxlovid, First Oral Therapy for COVID-19

Given within three days of symptom onset, the pill combination was nearly 90 percent effective at preventing high-risk patients from developing severe illness in a clinical study.

Given within three days of symptom onset, the pill combination was nearly 90 percent effective at preventing high-risk patients from developing severe illness in a clinical study.

ABOVE: © ISTOCK.COM, KENISHIROTIE

emergency use authorization (EUA)

building sign
Johnson & Johnson Vaccine Garners First Full Approval
Chloe Tenn | Nov 24, 2021
Health Canada has given the single COVID-19 shot the official greenlight for use in people 18 and older.
convalescent plasma covid-19 coronavirus pandemic sars-cov-2 antibodies clinical trial NIH emergency use authorization
NIH Halts Outpatient COVID-19 Convalescent Plasma Trial
Marcus A. Banks | Mar 4, 2021
The decision adds to evidence that the benefits of plasma infusions from COVID-19 survivors may be limited, but advocates say the case isn’t closed.
COVID-19, SARS-CoV-2, Johnson & Johnson, Pfizer, Moderna, vaccine, vaccination, variant, FDA
US Authorizes a Third COVID-19 Vaccine
Asher Jones | Mar 1, 2021
Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.
Opinion: Emergency Use Authorizations Are a Threat to Science 
Kevin J. Tracey, Christina Brennan | Dec 1, 2020
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.